20 results about "Aztreonam" patented technology

The invention provides application of magnoflorine in preparation of beta-lactamase inhibitors and antibacterial drugs, and belongs to the technical field of research and development of bacterial drug-resistant drugs. According to the invention, magnoflorine is creatively used as a beta-lactamase inhibitor; meanwhile, the magnoflorine is combined with the ceftazidime or the aztreonam for use, so that the sensitivity of various bacteria to the ceftazidime or the aztreonam is obviously enhanced; in addition, the antibacterial pharmaceutical composition provided by the invention is used as a drug containing a beta-lactamase inhibitor, and is used for resisting drug-resistant bacteria generating beta-lactamase together with beta-lactam antibiotics.

The invention discloses aztreonam microspheres as well as a preparation method and application thereof. The microsphere is an inhalation preparation and can be effectively deposited in the lung, so that the slow release of the medicine is realized. According to the aztreonam microspheres, aztreonam and cinnamyl aldehyde are synthesized into a small molecule drug, and the small molecule drug is self-assembled into the microspheres. The preparation method comprises the following steps: (1) placing aztreonam AZT and cinnamyl aldehyde CA in a glass bottle according to a molar ratio of 3: 2, adding dimethyl sulfoxide DMSO, stirring and dissolving, and stirring and reacting at room temperature for 5-7 hours; (2) dialyzing the reacted solution in a dialysis bag, removing DMSO and unreacted small molecules, and obtaining dialysate after 48 hours; (3) performing freeze drying to obtain yellow powder of cinnamyl aldehyde-aztreonam CAT; and (4) weighing the CAT powder, dissolving the CAT powder in deionized water, and shaking to dissolve the CAT powder to obtain the aztreonam microspheres. The microspheres are suitable for treatment of pulmonary infections, in particular for local drug delivery and sustained release control.

The invention provides a preparation method of aztreonam for injection, which is characterized by comprising the following steps: under the conditions that the temperature is controlled at 18-26 DEG C and the relative humidity is less than or equal to 55%, feeding aztreonam and arginine into a lifting mixer according to the mass ratio of 1: (0.77-0.80) in an alternate pumping manner, and mixing. The product prepared by the method is stable and safe, and provides more reliable technical support for preparation of aztreonam for injection.

The invention discloses a separation, analysis and determination method of aztreonam and enantiomers thereof, and belongs to the technical field of pharmaceutical analysis. According to the method, silica gel surface covalently bonded O-9-(tert-butyl carbamoyl) quinine is adopted as a filler (QN-AX, 4.6 mm * 150mm, 5 [mu] m), and methanol / acetonitrile / acetic acid / triethylamine = 50 / 50 / 2 / 1.6 (v / v / v / v) is adopted as a mobile phase for isocratic elution. The method can simply, accurately and efficiently analyze and detect aztreonam and the enantiomer thereof, and effectively control the quality of aztreonam and the enantiomer thereof.

The invention relates to the technical field of drug conjugates and pharmaceutical compositions, and discloses an antibacterial aztreonam main ring-aggregation-induced emission molecule-siderophore conjugate, TPAT-A has good fluorescence imaging capability on staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa and stenotrophomonas maltophilia, and can be used for preparing a drug conjugate for resisting bacteria, and the TPAT-A has good fluorescence imaging capability on staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa and stenotrophomonas maltophilia. Selective imaging of bacteria in a complex biological sample can be realized, and the monitoring capability of pathogenic bacterium infection is effectively improved; meanwhile, under the illumination condition, the TPAT-A has a good killing effect on staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii and stenotrophomonas maltophilia. TPAT-A is difficult to recognize part of gram-negative bacteria and generate a killing effect due to the fact that the gram-negative bacteria have a more complex membrane structure, and lipopolysaccharide existing on an outer membrane can effectively prevent foreign molecules from entering cells; therefore, the gram-negative bacteria have higher tolerance to antibiotics, and infection caused by the gram-negative bacteria is more difficult to treat clinically.

Novel Compound The present invention relates to a pseudopaline analogue-aztreonam conjugate. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially P. aeruginosa bacteria infections.

The invention relates to the technical field of medicines, in particular to application of combination of meropenem or aztreonam and paromomycin sulfate in preparation of antibacterial drugs. The experimental result of the in vitro combination effect shows that when meropenem or aztreonam is combined with paromomycin sulfate, the meropenem or aztreonam has a remarkable synergistic effect on carbapenem-resistant klebsiella pneumoniae, and paromomycin sulfate can reduce the bacteriostatic concentration of meropenem or aztreonam, so that the meropenem or aztreonam can be used for preparing the medicine for treating the carbapenem-resistant klebsiella pneumoniae. Therefore, the paromomycin sulfate can be used for improving the inhibition effect of meropenem or aztreonam on carbapenem-resistant klebsiella pneumoniae.

The application discloses a combined drug sensitivity test method for rapidly detecting the synergistic effect of amikacin and ceftazidime-avibactam, and the method comprises the following steps: uniformly coating a to-be-detected bacterial suspension on an MH agar plate, firstly pasting two ATM paper sheets and two CZA paper sheets respectively, and ensuring that the four paper sheets are uniformly distributed on the plate; secondly, pasting a to-be-detected ATM drug sensitivity paper sheet on a to-be-detected CZA paper sheet, and indicating the CZA ATM ; thirdly, pasting a to-be-detected CZA drug sensitivity paper sheet on a to-be-detected ATM paper sheet, and indicating the ATM CZA ; fourthly, respectively dropping 20 μL of sterile normal saline on the CZA ATM and ATM CZA ; and finally, placing the plate in a 35℃ incubator for 8 hours, measuring the diameters of the bacteriostatic rings of ATM, CZA, ATM CZA and CZA ATM , and determining the synergistic effect according to the diameters of the bacteriostatic rings and the drug sensitivity breakpoint standard. The application has the advantages of simple operation, rapidness, accuracy, low cost and the like.

The invention discloses a culture medium for detecting streptococcus agalactiae in bovine mastitis and a test piece thereof, the culture medium comprises a nutritional ingredient mixture, a composite inhibitor, a composite chromogenic enzyme substrate and cold water gel, the composite inhibitor is aztreonam, nalidixic acid, potassium clavulanate and trimethoprim; the compound chromogenic enzyme substrate is 5-bromine-6-chloro-3-indole-phosphoric acid p-toluidine, 5-bromine-4-chloro-3-indole-beta-D-glucuronide, 5-bromine-6-chloro-3-indole-beta-D-glucopyranoside, and 5-bromine-6-chloro-3-indole-beta-D-galactoside, and the compound chromogenic enzyme substrate is a compound chromogenic enzyme. The composite inhibitor in the streptococcus agalactiae test piece can effectively inhibit growth of non-target bacteria, and the composite chromogenic enzyme substrate has higher selectivity on target bacteria, so that the test piece has the characteristics of high specificity, high sensitivity, short detection period, easiness in observation and low detection cost; the method has huge development potential and wide application prospect in pasture detection.

The invention discloses a freeze-dried preparation of aztreonam avibactam sodium for injection and a preparation method thereof, wherein the preparation method comprises freeze-drying an aqueous solution of aztreonam avibactam sodium, wherein the freeze-drying comprises sequentially pre-freeze-thaw, secondary freezing, sublimation drying and analytical drying; the pre-freeze-thaw comprises: cooling the aqueous solution of aztreonam avibactam sodium to ‑30-‑50° C., keeping for 2-6 hours, then heating to ‑10-0° C., keeping for 1-10 hours; the secondary freezing comprises: cooling to ‑30-‑50° C., keeping for 2-6 hours. In the present invention, the pre-freeze-thaw is firstly thawed and then re-frozen again during the freeze-drying process, so that the moisture content in the final freeze-dried product can be reduced to less than 1.0%, and the prepared freeze-dried preparation of aztreonam avibactam sodium for injection has low moisture and good stability.

The invention discloses a culture medium and a test piece for detecting common pathogenic bacteria of streptococcus in bovine mastitis, the culture medium comprises a nutritional ingredient mixture, a composite inhibitor, a composite chromogenic enzyme substrate and cold water gel, the composite inhibitor is aztreonam, nalidixic acid and potassium clavulanate; the compound chromogenic enzyme substrate is 5-bromine-6-chloro-3-indole-phosphoric acid p-toluidine and 5-bromine-4-chloro-3-indole-beta-D-glucuronide, and the compound chromogenic enzyme substrate is 5-bromine-6-chloro-3-indole-phosphoric acid p-toluidine. The test strip for the common pathogenic bacteria of the streptococcus family can be used for rapidly detecting the common pathogenic bacteria of the streptococcus family in cow mastitis in a dairy farm, has the characteristics of strong specificity, high sensitivity, short detection period, easiness in observation and low detection cost, and has huge development potential and wide application prospect in pasture detection.

The invention discloses a culture medium for detecting staphylococcus in bovine mastitis and a detection tablet thereof.The culture medium comprises a nutrient mixture, a composite inhibitor and a composite chromogenic enzyme substrate, and the composite inhibitor comprises aztreonam, potassium tellurite, nalidixic acid and polymyxin E; the compound chromogenic enzyme substrate is prepared from a mixture of 5-bromo-6-chloro-3-indolyl-toluidine phosphate salt and 5-bromo-4-chloro-3-indole-beta-D-glucopyranoside, and the compound chromogenic enzyme substrate is prepared by mixing the 5-bromo-6-chloro-3-indolyl-toluidine phosphate salt with the 5-bromo-4-chloro-3-indolyl-beta-D-glucopyranoside The compound inhibitor in the staphylococcus detection sheet can effectively inhibit growth of non-staphylococcus strains, and the compound chromogenic enzyme substrate has higher selectivity on target strains, so that the detection sheet has the characteristics of high sensitivity and high specificity, the detection accuracy of the staphylococcus strains is greatly improved, and the false positive rate and the false negative rate are reduced.

The invention discloses a drug-resistant pseudomonas aeruginosa PA-1, the preservation number of the drug-resistant pseudomonas aeruginosa PA-1 in Guangdong Microbiological Culture Collection Center is GDMCC No: 65733. According to the drug-resistant pseudomonas aeruginosa PA-1, drug sensitive experiments show that the drug-resistant pseudomonas aeruginosa PA-1 is resistant to imipenem, ceftazidime, piperacillin, ticarcillin, aztreonam, cefuroxime sodium, cefoxitin and ceftriaxone; a quantitative dilution method experiment shows that the strain is resistant to aztreonam, imipenem, piperacillin / tazobactam, piperacillin, ceftazidime and cefepime; the drug-resistant strain can be used for screening a pseudomonas aeruginosa bacteriostatic preparation, and a new way is provided for development of drugs for treating diseases caused by pseudomonas aeruginosa.

The invention discloses a pharmaceutical composition for inhibiting CRE and application, and relates to the technical field of drug research and development, and the key points of the technical scheme are as follows: the effect of aztreonam combined with four beta-lactamase inhibitors (avibactam, clavulanic acid, tazobactam and sulbactam) on 77 CRE isolates in Shenzhen children hospitals is evaluated. It is found that most of CRE isolates, resistant to aztreonam, in CRE isolates collected in Shenzhen children hospitals carry MBL and other beta-lactamase genes at the same time. And aztreonam / avibactam has good antibacterial activity on all the tested strains. For isolates which carry MBL genes but do not have AmpC enzyme coding genes, aztreonam / clavulanic acid can be used as a more economical and potential combination therapy regimen than aztreonam / avibactam, but is not suitable for CRE isolates carrying AmpC enzyme genes.

Enhanced stability for aztreonam is achieved by separate packaging of aztreonam and a physiologically acceptable liquid carrier therefor prior to constitution of an aztreonam solution suitable for administration by injection or inhalation. A manually activatable package having a chamber preferably containing anhydrous β-aztreonam powder and a separate chamber in the same package containing a solvent for the β-aztreonam powder for convenient constitution of β-aztreonam prior to administration is described.

The present application relates to the technical field of medicine, in particular to the application of meropenem or aztreonam combined with nalidixic acid in the preparation of antibacterial drugs. The checkerboard dilution method minimum inhibitory concentration test, dynamic time-kill curve and galleria mellonella animal test prove that nalidixic acid can enhance the antibacterial activity of meropenem or aztreonam against carbapenem-resistant klebsiella pneumoniae, reduce the minimum inhibitory concentration of meropenem or aztreonam against carbapenem-resistant klebsiella pneumoniae, and when meropenem or aztreonam is combined with nalidixic acid, the combination shows significant synergistic antibacterial effect in vitro and in vivo against carbapenem-resistant klebsiella pneumoniae. Meropenem combined with nalidixic acid has synergistic antibacterial effect against OXA-48, NDM, KPC, IMP, VIM-producing carbapenem-resistant klebsiella pneumoniae; aztreonam combined with nalidixic acid has synergistic antibacterial effect against KPC-producing carbapenem-resistant klebsiella pneumoniae.

Described are analogs of aztreonam and disulfiram of Formula I, II, and III. These compounds can be used to treat bacterial infections in a subject. Also disclosed is the use of aztreonam and disulfiram for treating H. pylori infections. Combinations of the disclosed analogs and / or aztreonam and disulfiram with additional antibiotics and proton pump inhibitors are also disclosed.

The invention relates to a non-coated rubber plug for Azidonam and aztreonam medicines and a preparation method thereof, and the non-coated rubber plug is prepared from the following raw materials in parts by weight: 90-100 parts of brominated butyl rubber, 70-80 parts of ethylene-vinyl alcohol copolymer, 7-10 parts of vulcanizing agent, 1-2 parts of activating agent, 5-10 parts of plasticizer, 0.5-1 part of thiourea and 25-40 parts of coarsened glass fiber and diethylenetriamine modified thiourea mixture, the non-film-covered rubber plug for the aztreonam and aztreonam medicine has the advantages of low puncture exfoliation and air permeability.

The utility model discloses a storage tank for aztreonam monocyclic mother nucleus production, which belongs to the technical field of chemical production and comprises a tank body, a motor is mounted at the top of the tank body, a driving component is fixedly connected onto an output shaft of the motor, the driving component is clamped on the tank body through a bearing seat, and a turntable is clamped outside the driving component. According to the storage tank for aztreonam single-ring mother nucleus production, a knocking assembly is driven to rotate through a rotary disc, a knocking wheel in the knocking assembly can roll on the inner wall of a supporting assembly, when the knocking wheel makes contact with the inclined face of a guide block, the knocking wheel is pressed to drive a sliding column to slide in a stand column, and when the knocking wheel continues to rotate and is disengaged from the guide block, the sliding column slides in the stand column. The sliding column is supported through the elastic force of the spring, the sliding column can drive the knocking wheel to rapidly knock the supporting assembly, the supporting assembly transmits the vibration sense into the tank body, materials attached to the inner wall of the tank body can be shaken off, therefore, the residual materials in the tank body can be conveniently cleaned, and the storage quality of the follow-up materials is guaranteed.

The invention relates to the technical field of medicines, in particular to application of combination of meropenem or aztreonam and nalidixic acid in preparation of antibacterial drugs. A chessboard dilution method minimum inhibitory concentration test, a dynamic time-sterilization curve and a greater wax moth animal test prove that nalidixic acid can enhance the antibacterial activity of meropenem or aztreonam to carbapenem-resistant klebsiella pneumoniae; the minimum inhibitory concentration of meropenem or aztreonam on carbapenem-resistant klebsiella pneumonia is reduced, and meropenem or aztreonam shows a remarkable in-vivo and in-vitro synergistic antibacterial effect on carbapenem-resistant klebsiella pneumonia when being combined with nalidixic acid. The combination of meropenem and nalidixic acid has a synergistic antibacterial effect on carbapenem-resistant klebsiella pneumoniae producing OXA-48, NDM, KPC, IMP and VIM; the aztreonam and the nalidixic acid are combined for use, so that a synergistic antibacterial effect is achieved on carbapenem-resistant klebsiella pneumoniae for producing KPC.